Dropaxin

Quick links to important sections

Dropaxin

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dropaxin

Quick Facts

Property Description
Active ingredient Paroxetine (as the hydrochloride hemihydrate)
Form Primarily film-coated tablets and oral suspension
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulating serotonin levels to help regulate mood
Origin Synthetic compound

Defining Dropaxin: Active Ingredient and Pharmacological Class

Dropaxin is a Prescription-only medicine (POM) centered on the single active ingredient Paroxetine, which is chemically defined as a synthetic antidepressant. It operates primarily as a Selective Serotonin Reuptake Inhibitor (SSRI), a globally recognized class of drugs utilized to modify imbalances in specific neurochemical messengers. Paroxetine is used specifically to restore serotonin balance in the brain, helping to stabilize necessary neurochemical functions. The medication is designed to address underlying chemical factors, an approach used for managing conditions associated with serotonin dysfunction.

Composition, Forms, and General Therapeutic Purpose

The entirety of Dropaxin's therapeutic action stems from its core component, Paroxetine, a precisely manufactured synthetic compound. For patient use, the drug is primarily designed for the oral route and is commonly available as film-coated tablets and, depending on the pharmaceutical market, may also be offered as an oral suspension. The main pharmacological function of Paroxetine is the potent and selective inhibition of 5-hydroxytryptamine (serotonin) reuptake. This established mechanism indicates the drug’s role in restoring the chemical stability required for regulating mood. The fundamental purpose of this medication, regardless of its final form, is to modulate the brain's neurochemical balance, targeting the serotonergic system to help reestablish stability and functional signaling.

SSRI Mechanism and Unique Classification

The specific classification of Dropaxin as an SSRI directly corresponds to its method of action: inhibition of neuronal serotonin reuptake. This means the compound physically prevents the rapid reabsorption of the neurotransmitter serotonin by nerve cells, effectively increasing the concentration of this essential chemical in the spaces between neurons. This targeted focus on the serotonergic system differentiates Paroxetine from older, less-selective pharmacological agents, confirming its place as a dedicated therapeutic tool for specific neurochemical intervention. The efficacy and specificity of this SSRI mechanism are designed to normalize receptor activity in the brain.

Regulatory References

  1. U.S. National Library of Medicine - Paroxetine
  2. MedlinePlus Drug Information - Paroxetine

What side effects are possible with Dropaxin?

Dropaxin (Paroxetine) is associated with an official safety profile that details adverse reactions across several physiological systems and distinct frequency classifications. Nausea, increased sweating (hyperhidrosis), and various forms of sexual dysfunction (e.g., abnormal ejaculation, decreased libido) are listed in regulatory documents as Very Common side effects, meaning they may affect more than 1 in 10 people.

Reactions classified as Common (ge 1/100 to <1/10) often affect the Gastrointestinal (dry mouth, constipation, diarrhea) and Nervous Systems (dizziness, tremor, somnolence, insomnia). Uncommon effects include akathisia (psychomotor restlessness).

Serious Safety Considerations

The official labeling includes mandatory warnings concerning serious adverse reactions. This includes the potential for Serotonin Syndrome and the risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults (under 24 years old), most notably during the first few months of treatment or following a dose change. The risk of angle-closure glaucoma and clinically significant bleeding events are also documented.

Population and Contextual Safety Notes

The medication is not recommended for use in children and adolescents under 18 due to documented increased frequency of suicidal behaviors and hostility. Safety notes also address special populations, including individuals with severe hepatic or renal impairment, who may experience increased plasma concentrations of the drug. Furthermore, its use is contraindicated in combination with Monoamine Oxidase Inhibitors (MAOIs), Pimozide, and Thioridazine due to high-level safety risks. The official label also notes that sudden discontinuation can result in a withdrawal syndrome.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Dropaxin (Paroxetine) overdose defines both the expected clinical manifestations and the required emergency response. Overdose presentations commonly include non-specific signs such as drowsiness, nausea, vomiting, dizziness, diaphoresis (sweating), and tremor. More specific signs like mydriasis (pupil dilation) and sinus tachycardia (rapid heart rate) are also documented.

Severe or life-threatening outcomes are possible, necessitating prompt attention. These outcomes may include serotonin syndrome, convulsions (seizures), coma, and severe ventricular arrhythmias or other cardiac toxicity. Fatal outcomes have been reported, particularly when Paroxetine is consumed in a mixed overdose involving alcohol or other psychoactive medicines, a factor officially noted to increase severity.

Immediate medical attention must be sought for any suspected overdose. Because no specific antidote is known for Paroxetine, management is focused entirely on symptomatic and supportive treatment. This mandated procedure often includes close observation and intensive hospital monitoring for signs of CNS or cardiovascular dysfunction. Supportive measures, such as the use of activated charcoal or gastric lavage, may be considered based on the officially described protocols for acute overdose management.

Therapeutic Uses of Dropaxin

What Dropaxin Treats: Main Uses and Benefits

Paroxetine (Dropaxin) is utilized across several major psychological and physiological domains. It is commonly used for managing Major Depressive Disorder (MDD), Panic Disorder, Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD).

The medication is relevant in conditions characterized by periods of heightened symptoms, specifically addressing the pervasive symptoms of low mood, severe sadness, and loss of interest or pleasure. It assists with maintaining functional stability by managing the intensity of chronic, excessive worry that creates noticeable functional strain, providing support that helps ease the overall symptom burden. It is generally applied when symptoms create noticeable functional strain, reflecting its role in supportive symptom management rather than cure.

It is relevant for managing symptoms that interfere with daily comfort, including the intense cycle of unwanted obsessions and ritualized compulsions seen in OCD. The medication is also used in situations involving certain distressing symptoms in Premenstrual Dysphoric Disorder (PMDD). Furthermore, it is used to help with moderate to severe vasomotor symptoms (hot flashes and night sweats) associated with menopause, and may assist with maintaining functional stability when these symptoms interfere with routine activities.


Quick Fact: Relief for Key Symptom Clusters
Focus Symptom Category
Mood Stabilization Pervasive depressed mood and anhedonia
Anxiety Control Panic attacks and excessive, chronic worry
Cognitive Patterns Intrusive obsessions and compulsions
Physiological Support Severe vasomotor symptoms (hot flashes)

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Dropaxin (Paroxetine) eligibility is strictly defined by government regulatory documents, focusing on patient age, current medications, and pre-existing health conditions.

Absolute Non-Eligibility

The medicine is contraindicated and must not be used by patients concurrently taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of stopping one. This prohibition also applies to patients taking Thioridazine or Pimozide, and those with a confirmed hypersensitivity to Paroxetine or any of its components.

Age and Physiological Restrictions

Dropaxin is primarily approved for adults (18 years and older). It is not approved or not recommended for psychiatric use in children and adolescents as safety and efficacy have not been established in this population. Use is generally not recommended during pregnancy due to noted risks, including an association with cardiovascular malformations in the first trimester and Persistent Pulmonary Hypertension of the Newborn (PPHN) later in gestation. Discontinuation of the drug or nursing is advised for lactating women.

Conditional Use

Use is conditional for elderly patients and those with severe hepatic or renal impairment, requiring a mandatory reduced initial dosage due to altered drug clearance. Caution and patient screening are also required for individuals with a history of bipolar disorder or seizures.

What should I know about interactions with other medicines?

Dropaxin (a Selective Serotonin Reuptake Inhibitor, or SSRI) can interact with a wide range of other medicines, supplements, and substances, leading to serious adverse effects.

Contraindicated Combinations (Do Not Use Together)

Interacting Medicine Class Potential Risk Key Action
Monoamine Oxidase Inhibitors (MAOIs) Life-threatening Serotonin Syndrome (high fever, agitation, confusion) Wait at least 14 days after stopping an MAOI before starting Dropaxin, and vice versa.
Pimozide Increased blood levels of Pimozide, potentially leading to serious heart rhythm problems. Use is strictly contraindicated.

Combinations Requiring Caution and Monitoring

Combining Dropaxin with other serotonergic medicines (such as Triptans, Tricyclic Antidepressants, Fentanyl, Tramadol, Tryptophan, or the herbal supplement St. John's Wort) significantly increases the risk of Serotonin Syndrome.

Medicines that affect blood clotting, such as the anticoagulant Warfarin, antiplatelet medicines (like Aspirin or NSAIDs), or other Selective Serotonin Reuptake Inhibitors (SSRIs), can increase the risk of bleeding or bruising when taken with Dropaxin. Close monitoring is necessary.

Other medicines, including Cimetidine, Phenytoin, and Phenobarbital, may also interact with Dropaxin by affecting its metabolism, potentially changing its effectiveness or side effects.

Dropaxin and Alcohol

Consumption of alcohol is strongly discouraged during treatment. Alcohol can worsen the central nervous system side effects of Dropaxin, such as dizziness and drowsiness, and may worsen the underlying symptoms of depression or anxiety.

Mechanism of Action

How Dropaxin Works: Mechanism of Action

Dropaxin primarily exerts its action in the central nervous system as a selective inhibitor of the Serotonin Transporter (SERT) protein. The SERT protein functions to clear the neurotransmitter serotonin (5- HT) from the synaptic cleft via reuptake into the presynaptic neuron. By binding to SERT and inhibiting this reabsorption process, Dropaxin rapidly causes an elevation of serotonin concentration in the synapse, prolonging its presence and enhancing chemical communication between neurons.

This sustained increase in synaptic serotonin subsequently triggers a slower process of neuronal adaptation. This involves cellular changes, including the down-regulation and desensitization of certain 5- HT receptors over time. The combined effect of acute SERT blockade and chronic receptor modification targets the Central Serotonergic System, altering the signaling dynamics within neurocircuits that project to regulatory regions of the brain. This results in the progressive establishment of the drug's distinctive physiological effect profile.

Dosage and Administration Information

How Dropaxin is Used: Official Administration Guidelines

Dropaxin (Paroxetine) is a medication approved for oral administration only. It is available in various forms, including immediate-release tablets, an oral suspension (10 mg/5 mL), and extended-release (CR) tablets. The specific dosage and regimen are established to ensure standardized application based on the condition being addressed.


Administration and Dosage Principles

Guideline Domain Official Use Principles
Route & Forms Exclusively oral via immediate-release tablets, extended-release tablets, or oral suspension. Extended-release tablets must be swallowed whole and must not be crushed or chewed.
Frequency Typically administered as a single daily dose, often in the morning. The oral suspension requires shaking well before use.
Dosing & Titration Treatment begins with a low initial dose (e.g., 10 mg or 20 mg for IR) followed by gradual dose increases (titration) in small increments (10 mg or 12.5 mg) at intervals of at least one week.
Timing & Food The medication may be taken with or without food.

Population and Duration Patterns

The usage protocol specifies adjustments for certain patient groups. Older adults (geriatric patients) and those with severe hepatic or renal impairment require a reduced starting dose (10 mg or 12.5 mg daily) and have lower limits on the maximum allowed dose.

Dropaxin is typically prescribed as part of a long-term treatment plan; for example, the clinical recommendation for depression is often a course of at least six months. Upon eventual cessation, the dosage must be gradually reduced (tapered) over several weeks rather than stopped abruptly.

Recent Clinical Evidence

Dropaxin: Recent Clinical Evidence

Research into Dropaxin (Paroxetine) was evaluated in controlled clinical trials, which provided the data reviewed by global regulatory agencies. The available research describes how the compound was studied for its approved uses and what patterns were observed in the patient populations.


Evidence for Use in Mood and Anxiety Conditions

The evidence base for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) relies on numerous short-term Randomized Controlled Trials (RCTs) and meta-analyses. These studies monitored symptom evolution using specialized scales. Research highlights that the measured effect compared to placebo was often described as modest, and comparative evidence against other compounds showed varied patterns. Studies for Panic Disorder and Obsessive-Compulsive Disorder also examined acute changes, but detailed, indication-specific trial information remains insufficient.


Evidence for Use in Women's Health

Dropaxin was evaluated for two conditions: Premenstrual Dysphoric Disorder (PMDD) and Vasomotor Symptoms (VMS). Research for PMDD monitored patient response over multiple cycles, observing changes in affective symptoms with greater frequency than physical symptoms. VMS evidence from pivotal Phase 3 RCTs examined differences in weekly hot flash frequency. A certain portion of the observed response in VMS studies was associated with the placebo group, and findings were mixed regarding sleep quality measurements.


Long-Term Follow-up and Remaining Uncertainties

Research has been conducted in older adults for MDD, but data for certain groups with specific medical comorbidities remain insufficient. While maintenance studies have been conducted for up to 18 months, long-term effects are not fully established across all uses. The overall picture shows that comparative evidence is lacking against newer treatments, and study results apply only to the populations observed.

Frequently Asked Questions (FAQ)

Common questions about Dropaxin (FAQ)


Q: If I miss a dose of Dropaxin, what is the generally accepted advice?

Official regulatory guidance describes that the missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the official recommendation is to skip the missed dose and continue with the regular schedule. Regulatory guidance emphasizes that two doses are not to be taken at the same time.


Q: Can Dropaxin cause fatigue or tiredness during the day?

Clinical trials reported that asthenia, which is described as physical weakness or a general lack of energy, is an adverse reaction. This finding is included in the medicine’s official safety profile provided to regulatory agencies.


Q: Is Dropaxin a type of controlled substance?

According to regulatory classification in the U.S., the active ingredient in Dropaxin (Paroxetine) is not designated as a controlled substance under the U.S. Controlled Substances Act.


Q: How long does Dropaxin stay in your system after stopping it?

Pharmacokinetic information indicates that the active ingredient has an elimination half-life of approximately 15 to 20 hours after a single dose of the controlled-release form. The half-life describes the time required for the amount of medication in the body to decrease by half.


Q: What should I do if the side effects of Dropaxin feel bothersome or if I feel worse?

Official medication guides advise patients and caregivers to be vigilant for the emergence or worsening of depression, changes in mood, or suicidal thoughts and behaviors, especially early in treatment or after a dose change. If these or any other severe symptoms appear, official guidelines suggest seeking medical advice immediately.


Q: Does taking Dropaxin impact my ability to drive or operate machinery?

Official warnings caution that central nervous system side effects such as drowsiness and dizziness are associated with the medicine. Regulatory warnings state that caution is necessary when engaging in potentially hazardous tasks, such as driving or operating heavy machinery, until the user knows how the drug affects them.


Q: What are the general long-term expectations for using Dropaxin?

Regulatory documentation indicates that studies have demonstrated the efficacy of the active ingredient in maintaining a therapeutic response in certain conditions for up to one year in placebo-controlled maintenance trials.


Q: Is it necessary to take Dropaxin at the exact same time every day?

The official prescribing information states the medicine should be taken exactly as prescribed, typically as a single daily dose. While general consistency is often implied, regulatory documents do not explicitly mandate taking the medicine at the exact same minute every day.


Q: What are the signs of a more serious, but rare, side effect of Dropaxin?

Official warnings detail that symptoms related to serious reactions, such as Serotonin Syndrome, can include agitation, hallucinations, coma, muscle twitching, rapid heart rate, or high fever. Official documentation describes the need for monitoring for these specific signs.


Q: Has there been much research done on the effectiveness of Dropaxin?

The regulatory approval for Dropaxin's stated indications is supported by data that has undergone review by agencies worldwide. The body of evidence is based on results gathered from controlled clinical trials and long-term maintenance studies reviewed by regulatory bodies.


Q: Do I need to change my diet while I am on Dropaxin?

The official label states that the medicine may be taken with or without food. However, official safety notes advise against the concurrent consumption of alcohol as it may worsen certain central nervous system side effects associated with the drug.


Q: Can men and women use Dropaxin equally?

The efficacy and safety of the medication are established for adults of both genders for the approved uses. Official adverse reaction tables indicate that various forms of sexual dysfunction are listed as common side effects for both male and female patients.


Q: What happens if I accidentally take two doses of Dropaxin?

Official guidance recommends contacting a healthcare provider or a poison control center immediately, or otherwise seeking emergency treatment if two doses are accidentally taken.


Q: Why do some people need to take Dropaxin for a long time?

Regulatory information highlights that conditions such as depression are associated with a risk of clinical worsening and suicide-related events. This risk is known to persist until significant and sustained remission occurs, often necessitating a long course of treatment to maintain stability.


Q: What are the recommended procedures for stopping Dropaxin if needed?

Official regulatory guidance requires that if the medicine is to be stopped, the dosage must be gradually reduced (a process known as tapering) over a period of several weeks. This controlled procedure is recommended by regulatory guidance to minimize the risk of discontinuation or withdrawal symptoms.


Q: Is there a generic version of Dropaxin available?

The active ingredient in Dropaxin is Paroxetine. This is the non-proprietary name that is used for the generic formulation of the medicine.


Q: Is Dropaxin known to cause headaches?

Official adverse reaction reports list headache as an effect reported during clinical trials. Additionally, headache is a symptom that may be experienced during the required process of discontinuation of the medicine.


Q: Can I take Dropaxin if I have a history of heart problems?

The official precautions section of the medicine's label advises patients to inform their healthcare provider if they have a history of or currently have heart problems before starting treatment with Dropaxin.


Q: Can Dropaxin affect vision?

Official warnings indicate that the use of Dropaxin is associated with a specific, rare safety risk known as angle-closure glaucoma. Regulatory guidance advises that patients should be screened for this risk factor prior to use.

How should Dropaxin be stored and disposed of?

Storage and Disposal of Dropaxin (Paroxetine)

Dropaxin must be stored at controlled room temperature, maintained between 20 C and 25 C (68 F and 77 F). To maintain product stability, the medication must be kept in its original container and the container must remain tightly closed.

Storage Protection and Safety

The tablets require protection from excess moisture and the oral suspension must be protected from freezing. The medication is required to be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired Dropaxin must be disposed of according to local requirements. It must not be disposed of via wastewater or placed into household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dropaxin found in:

A-Z Index: